Develops antibody-based immunotherapies for cancer treatment, focusing on activating innate immunity to target tumor cells.
Innate Pharma S.A., a prominent biotechnology company based in Marseille, France, specializes in the discovery, development, and commercialization of therapeutic antibodies primarily for treating various oncology indications worldwide. The company's robust pipeline includes several innovative products at various stages of clinical development and preclinical research. Among its key products is Lacutamab (IPH4102), an anti-KIR3DL2 antibody currently undergoing Phase II clinical trials for cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and refractory sezary syndrome.
Innate Pharma is also advancing Monalizumab, an immune checkpoint inhibitor in Phase III trials targeting advanced solid tumors like colorectal and lung cancers, along with head and neck cancer. Another promising candidate is Avdoralimab (IPH5401), a monoclonal antibody targeting the C5a receptor, currently in Phase II trials for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. Additionally, the company is exploring IPH5201 and IPH5301, antibodies targeting the CD39 and CD73 pathways respectively, to enhance antitumor immunity.
Founded in 1999, Innate Pharma S.A. has forged strategic partnerships and collaborations with leading pharmaceutical companies such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. These alliances underscore its commitment to advancing innovative therapies and expanding its therapeutic portfolio in the oncology space, leveraging its deep expertise in antibody-based therapies. The company continues to pioneer advancements in biopharmaceutical research aimed at addressing significant unmet medical needs across a spectrum of cancer types and immune-related disorders.